Trial Profile
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms ARTEMIS
- Sponsors AstraZeneca
- 18 Nov 2019 Results (n=6135) assessing copayment assistance interventions utilized when available and their impact on medication persistence were presented at the American Heart Association Scientific Sessions 2019
- 01 Jan 2019 Results assessing the co-payments impact on P2Y12 inhibitor use and major cardiovascular events published in the JAMA: the Journal of the American Medical Association
- 14 Nov 2018 Results assessing the "Halo Effect" of a P2Y12 Inhibitor Copayment Reduction Intervention on Persistence and Adherence With Other Secondary Prevention Medications, presented at the 91st Annual Scientific Sessions of the American Heart Association